Silver Book

Silver Book Fact

Vaccines save lives and money

Between 2001 and 2010, vaccine use prevented an estimated 170,000 severe pneumococcal infections and 10,000 deaths, and saved an estimated $310 million in direct medical costs each year.

Frieden T. Antibiotic Resistance and the Threat to Public Health: Statement of Thomas Friden, MD, MPH, Director of the CDC: before the Committee on Energy and Commerce Subcommittee on Health, U.S. House of Representatives; 2010. http://www.cdc.gov/drugresistance/pdf/FriedenTestimony42810.pdf

Reference

Title
Antibiotic Resistance and the Threat to Public Health: Statement of Thomas Friden, MD, MPH, Director of the CDC: before the Committee on Energy and Commerce Subcommittee on Health, U.S. House of Representatives
Publication Date
2010
Authors
Frieden T
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value
  • Economic Value

Related Facts

  • Global use of vaccine prevents death
    Compared to estimated deaths without vaccination, global use of vaccination in 2001 prevented: 61% of measles deaths; 69% of tetanus deaths; 78% of pertussis (whooping cough) deaths; 94% of diphtheria…  
  • Staff flu vaccination reduces incidence of staff and patients
    Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from…  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…  
  • Annual flu vaccine could save 275,000 QALYs
    Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.…  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.